Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foralumab in NASH and T2DM
NCT03291249Phase 2Withdrawn
- Sponsor
- Tiziana Life Sciences
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of foralumab in Nonalcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM), sponsored by Tiziana Life Sciences. Planned start Dec 2017; status: withdrawn.
02
Drugs
foralumab
03
Conditions
Nonalcoholic steatohepatitis (NASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03291249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291249.